Lillian M. Smyth
Australian National University(AU)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research, Protein Degradation and Inhibitors, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers(2018)980 cited
- → HER kinase inhibition in patients with HER2- and HER3-mutant cancers(2018)769 cited
- → AKT Inhibition in Solid Tumors With AKT1 Mutations(2017)319 cited
- → Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS(2021)176 cited
- → Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression(2015)130 cited
- → Imlunestrant with or without Abemaciclib in Advanced Breast Cancer(2024)118 cited
- → Efficacy and Determinants of Response to HER Kinase Inhibition in HER2 -Mutant Metastatic Breast Cancer(2019)108 cited
- → Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer(2020)99 cited
- → Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry(2020)49 cited
- → Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial(2024)44 cited